AU2001249626A1 - Cathepsin inhibitors in cancer treatment - Google Patents

Cathepsin inhibitors in cancer treatment

Info

Publication number
AU2001249626A1
AU2001249626A1 AU2001249626A AU4962601A AU2001249626A1 AU 2001249626 A1 AU2001249626 A1 AU 2001249626A1 AU 2001249626 A AU2001249626 A AU 2001249626A AU 4962601 A AU4962601 A AU 4962601A AU 2001249626 A1 AU2001249626 A1 AU 2001249626A1
Authority
AU
Australia
Prior art keywords
cancer treatment
cathepsin inhibitors
cathepsin
inhibitors
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249626A
Inventor
Fatih M. Uckun
De-Min Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Publication of AU2001249626A1 publication Critical patent/AU2001249626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001249626A 2000-03-31 2001-03-30 Cathepsin inhibitors in cancer treatment Abandoned AU2001249626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09539739 2000-03-31
US09/539,739 US6605589B1 (en) 2000-03-31 2000-03-31 Cathepsin inhibitors in cancer treatment
PCT/US2001/010196 WO2001074376A2 (en) 2000-03-31 2001-03-30 Cathepsin inhibitors in cancer treatment

Publications (1)

Publication Number Publication Date
AU2001249626A1 true AU2001249626A1 (en) 2001-10-15

Family

ID=24152451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249626A Abandoned AU2001249626A1 (en) 2000-03-31 2001-03-30 Cathepsin inhibitors in cancer treatment

Country Status (3)

Country Link
US (2) US6605589B1 (en)
AU (1) AU2001249626A1 (en)
WO (1) WO2001074376A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19940130A1 (en) * 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
US6605589B1 (en) * 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment
US7368421B2 (en) * 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
WO2003015768A2 (en) * 2001-08-16 2003-02-27 Probiodrug Ag Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) * 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
PT1620082E (en) * 2003-05-05 2010-06-11 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer`s disease and down syndrome
EP1620091B1 (en) * 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
JP5707014B2 (en) * 2003-10-15 2015-04-22 プロビオドルグ エージー Use of glutaminyl and glutamate cyclase effectors
US7632972B2 (en) * 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
KR101099206B1 (en) 2004-02-05 2011-12-27 프로비오드룩 아게 Novel Inhibitors of Glutaminyl Cyclase
WO2006068742A2 (en) * 2004-11-19 2006-06-29 Children's Memorial Hospital Use of cathepsin inhibitors for reversing or preventing resistance of a cancer cell to a cytotoxic agent
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
KR20090020585A (en) 2006-05-19 2009-02-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
US10369171B2 (en) * 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008112917A2 (en) * 2007-03-13 2008-09-18 Uti Limited Partnership Peptidyl fluoromethylketones as inhibitors of viral replication
JP5896746B2 (en) 2009-02-09 2016-03-30 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Design, synthesis and evaluation of procaspase activating compounds as individualized anticancer drugs
JP5234550B2 (en) * 2010-03-01 2013-07-10 独立行政法人科学技術振興機構 VDAC function regulator
US20160101076A1 (en) * 2013-05-15 2016-04-14 Ronald J. Weigel Use of Sumoylation Inhibitors for Treating Cancer
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy
WO2018163204A1 (en) 2017-03-08 2018-09-13 Yogee's Bioinnovations Private Limited Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer
EP3884948A1 (en) * 2020-03-26 2021-09-29 Ecole Polytechnique Fédérale de Lausanne (EPFL) Cathepsin inhibitors and uses thereof
WO2024168138A2 (en) * 2023-02-08 2024-08-15 Iogenetics, Llc Expedited neoantigen vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
PL328877A1 (en) * 1995-10-30 1999-03-01 Smithkline Beecham Corp Method of inhibiting cathepsin k
US5883121A (en) 1995-12-12 1999-03-16 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivative or salt thereof, and medicine comprising the same
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU779177B2 (en) * 1999-03-15 2005-01-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
WO2001044464A1 (en) 1999-12-15 2001-06-21 Mcgill University Targeting of endosomal growth factor processing as anti-cancer therapy
US6605589B1 (en) * 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment

Also Published As

Publication number Publication date
US20040005329A1 (en) 2004-01-08
US6605589B1 (en) 2003-08-12
WO2001074376A3 (en) 2002-02-07
WO2001074376A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
IL251270A0 (en) Cancer treatment
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2002223827A1 (en) Well treatment
AU2002258990A1 (en) Improvements in ablation therapy
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
EP1383492A4 (en) Molecular conjugates for use in treatment of cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AU2001236929A1 (en) Surface treatment
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001257325A1 (en) Cancer treatment
AU2001276462A1 (en) Use of natural products in cancer treatment
GB0026015D0 (en) Cancer treatment
AU2001261324A1 (en) Psoriasis treatment
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AU2001282349A1 (en) Fluid treatment
AU2001247922A1 (en) Calpain inhibitors in cancer treatment
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment